Mostrar el registro sencillo del ítem
dc.contributor.author
Cohen, Jordana B.
dc.contributor.author
Hanff, Thomas C.
dc.contributor.author
William, Preethi
dc.contributor.author
Sweitzer, Nancy
dc.contributor.author
Rosado Santander, Nelson R.
dc.contributor.author
Medina, Carola
dc.contributor.author
Rodriguez-Mori, Juan E
dc.contributor.author
Renna, Nicolas Federico
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Chang, Tara I.
dc.contributor.author
Corrales Medina, Vicente
dc.contributor.author
Andrade Villanueva, Jaime F.
dc.contributor.author
Barbagelata, Alejandro
dc.contributor.author
Cristodulo Cortez, Roberto
dc.contributor.author
Díaz-Cucho, Omar A
dc.contributor.author
Spaak, Jonas
dc.contributor.author
Alfonso, Carlos E.
dc.contributor.author
Valdivia Vega, Renzo
dc.contributor.author
Villavicencio Carranza, Mirko
dc.contributor.author
Ayala García, Ricardo J.
dc.contributor.author
Castro Callirgos, Carlos A.
dc.contributor.author
González Hernández, Luz A.
dc.contributor.author
Bernales Salas, Eduardo F.
dc.contributor.author
Coacalla Guerra, Johanna C.
dc.contributor.author
Salinas Herrera, Cynthia D.
dc.contributor.author
Nicolosi, Liliana
dc.contributor.author
Basconcel, Mauro
dc.contributor.author
Byrd, James B.
dc.contributor.author
Sharkoski, Tiffany
dc.contributor.author
Bendezú Huasasquiche, Luis E.
dc.contributor.author
Chittams, Jesse
dc.contributor.author
Edmonston, Daniel L.
dc.contributor.author
Vasquez, Charles R.
dc.contributor.author
Chirinos, Julio A.
dc.date.available
2021-06-30T14:45:46Z
dc.date.issued
2021-03
dc.identifier.citation
Cohen, Jordana B.; Hanff, Thomas C.; William, Preethi; Sweitzer, Nancy; Rosado Santander, Nelson R.; et al.; Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial; Elsevier; The Lancet Respiratory Medicine; 9; 3; 3-2021; 275-284
dc.identifier.issn
2213-2600
dc.identifier.uri
http://hdl.handle.net/11336/135156
dc.description.abstract
Background: Biological considerations suggest that renin–angiotensin system inhibitors might influence the severity of COVID-19. We aimed to evaluate whether continuing versus discontinuing renin–angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) affects outcomes in patients admitted to hospital with COVID-19. Methods: The REPLACE COVID trial was a prospective, randomised, open-label trial done at 20 large referral hospitals in seven countries worldwide. Eligible participants were aged 18 years and older who were admitted to hospital with COVID-19 and were receiving a renin–angiotensin system inhibitor before admission. Individuals with contraindications to continuation or discontinuation of renin–angiotensin system inhibitor therapy were excluded. Participants were randomly assigned (1:1) to continuation or discontinuation of their renin–angiotensin system inhibitor using permuted block randomisation, with allocation concealed using a secure web-based randomisation system. The primary outcome was a global rank score in which participants were ranked across four hierarchical tiers incorporating time to death, duration of mechanical ventilation, time on renal replacement or vasopressor therapy, and multiorgan dysfunction during the hospitalisation. Primary analyses were done in the intention-to-treat population. The REPLACE COVID trial is registered with ClinicalTrials.gov, NCT04338009. Findings: Between March 31 and Aug 20, 2020, 152 participants were enrolled and randomly assigned to either continue or discontinue renin–angiotensin system inhibitor therapy (continuation group n=75; discontinuation group n=77). Mean age of participants was 62 years (SD 12), 68 (45%) were female, mean body-mass index was 33 kg/m2 (SD 8), and 79 (52%) had diabetes. Compared with discontinuation of renin–angiotensin system inhibitors, continuation had no effect on the global rank score (median rank 73 [IQR 40–110] for continuation vs 81 [38–117] for discontinuation; β-coefficient 8 [95% CI −13 to 29]). There were 16 (21%) of 75 participants in the continuation arm versus 14 (18%) of 77 in the discontinuation arm who required intensive care unit admission or invasive mechanical ventilation, and 11 (15%) of 75 participants in the continuation group versus ten (13%) of 77 in the discontinuation group died. 29 (39%) participants in the continuation group and 28 (36%) participants in the discontinuation group had at least one adverse event (χ2 test of adverse events between treatment groups p=0·77). There was no difference in blood pressure, serum potassium, or creatinine during follow-up across the two groups. Interpretation: Consistent with international society recommendations, renin–angiotensin system inhibitors can be safely continued in patients admitted to hospital with COVID-19. Funding: REPLACE COVID Investigators, REPLACE COVID Trial Social Fundraising Campaign, and FastGrants.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Elsevier
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
COVID-19
dc.subject
SRAA
dc.subject
Hipertension Arterial
dc.subject.classification
Sistemas Cardíaco y Cardiovascular
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Medicina Clínica
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2021-06-29T13:25:57Z
dc.identifier.eissn
2213-2619
dc.journal.volume
9
dc.journal.number
3
dc.journal.pagination
275-284
dc.journal.pais
Estados Unidos
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.description.fil
Fil: Cohen, Jordana B.. State University of Pennsylvania; Estados Unidos
dc.description.fil
Fil: Hanff, Thomas C.. State University of Pennsylvania; Estados Unidos
dc.description.fil
Fil: William, Preethi. University of Arizona; Estados Unidos
dc.description.fil
Fil: Sweitzer, Nancy. University of Arizona; Estados Unidos
dc.description.fil
Fil: Rosado Santander, Nelson R.. Hospital Nacional Carlos Alberto Seguin Escobedo; Perú
dc.description.fil
Fil: Medina, Carola. Hospital Nacional Edgardo Rebagliati Martins; Perú
dc.description.fil
Fil: Rodriguez-Mori, Juan E. Hospital Nacional Alberto Sabogal Sologuren; Perú
dc.description.fil
Fil: Renna, Nicolas Federico. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina. Universidad Nacional de Cuyo; Argentina
dc.description.fil
Fil: Chang, Tara I.. University of Stanford; Estados Unidos
dc.description.fil
Fil: Corrales Medina, Vicente. Ottawa Hospital Research Institute; Canadá
dc.description.fil
Fil: Andrade Villanueva, Jaime F.. Hospital Civil de Guadalajara; México
dc.description.fil
Fil: Barbagelata, Alejandro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. University of Duke; Estados Unidos
dc.description.fil
Fil: Cristodulo Cortez, Roberto. No especifíca;
dc.description.fil
Fil: Díaz-Cucho, Omar A. Hospital Alberto Leopoldo Barton Thompson; Perú
dc.description.fil
Fil: Spaak, Jonas. Danderyd University Hospital; Suecia
dc.description.fil
Fil: Alfonso, Carlos E.. University of Miami; Estados Unidos
dc.description.fil
Fil: Valdivia Vega, Renzo. Hospital Nacional Edgardo Rebagliati Martins; Perú
dc.description.fil
Fil: Villavicencio Carranza, Mirko. Hospital Nacional Edgardo Rebagliati Martins; Perú
dc.description.fil
Fil: Ayala García, Ricardo J.. Hospital Nacional Edgardo Rebagliati Martins; Perú
dc.description.fil
Fil: Castro Callirgos, Carlos A.. Hospital Nacional Edgardo Rebagliati Martins; Perú
dc.description.fil
Fil: González Hernández, Luz A.. Hospital Civil de Guadalajara; México
dc.description.fil
Fil: Bernales Salas, Eduardo F.. Hospital Nacional Carlos Alberto Seguin Escobedo; Perú
dc.description.fil
Fil: Coacalla Guerra, Johanna C.. Hospital Nacional Carlos Alberto Seguin Escobedo; Perú
dc.description.fil
Fil: Salinas Herrera, Cynthia D.. Hospital Nacional Carlos Alberto Seguin Escobedo; Perú
dc.description.fil
Fil: Nicolosi, Liliana. Hospital Espanol; Argentina
dc.description.fil
Fil: Basconcel, Mauro. Hospital Espanol; Argentina
dc.description.fil
Fil: Byrd, James B.. University of Michigan; Estados Unidos
dc.description.fil
Fil: Sharkoski, Tiffany. University of Pennsylvania; Estados Unidos
dc.description.fil
Fil: Bendezú Huasasquiche, Luis E.. Hospital Alberto Leopoldo Barton Thompson; Perú
dc.description.fil
Fil: Chittams, Jesse. University of Pennsylvania; Estados Unidos
dc.description.fil
Fil: Edmonston, Daniel L.. University of Duke; Estados Unidos
dc.description.fil
Fil: Vasquez, Charles R.. University of Pennsylvania; Estados Unidos
dc.description.fil
Fil: Chirinos, Julio A.. University of Pennsylvania; Estados Unidos
dc.journal.title
The Lancet Respiratory Medicine
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/S2213-2600(20)30558-0
Archivos asociados